More than 32,000 delegates from over 150 countries are attending this year’s Congress held in Paris, France. The critical importance of this meeting is underlined by recent news that cardiovascular disease mortality is now increasing in Europe, for the first time in 50 years. Global cardiovascular health is therefore an urgent priority.

Leading the news from the Congress was the release of five new guidelines from the Society, including guidelines for the management of dyslipidaemia and diabetes. LDL cholesterol is the indisputable primary lipid target; the Joint European Society of Cardiology/European Atherosclerosis Society Task Force have taken account of the clinical trials evidence and lowered LDL cholesterol goals in high and very high-risk patients.

Read the summary »

Watch a perspective from PCSK9 Forum Editor, Professor John Chapman

Watch it here »

Professor Kausik Ray (Imperial College, London, UK) presented date for the real-world use of evolocumab in familial hypercholesterolaemia in Europe.

Read the report and watch the video »

Professor Gregory Schwartz (University of Colorado School of Medicine, Aurora, Colorado, USA) discussed data from ODYSSEY OUTCOMES regarding the efficacy and safety of very low LDL cholesterol levels.

Read the report and watch the video »

Education: the primary mission of PCSK9 Forum.

Don’t forget to check back for the latest updates to the PCSK9 Forum educational slide resource programme